

Special Issue

Dissecting the Immunological Landscape of Human Malignancies

Message from the Guest Editor

This Special Issue will focus on novel tools, which are being developed to analyse the diversity of immune genes, proteins, cells and pathways in the tumour microenvironment. Powerful technologies, such as genome-wide association studies (GWAS), multiplexed immunohistochemistry, high-dimensional blood profiling of immune cells by flow cytometry and mass cytometry, are increasingly being integrated to assess immune competence and the likelihood of patients to respond to immunotherapy. A broader understanding of baseline immunity (the “immunoscore”), both in the periphery and in the tumour microenvironment, and of immune escape mechanisms is likely to expedite the identification of biomarkers that are predictive of clinical outcome and to foster the clinical implementation of a more refined and personalised approach to immune-based interventions.

Guest Editor

Prof. Dr. Sergio Rutella

College of Science and Technology, Clifton Campus, Nottingham Trent University, Nottingham NG11 8NS, UK

Deadline for manuscript submissions

closed (31 December 2017)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/10357

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).